Search Results - "Selkinski, I."

Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An interim review of a prospective, non-interventional study (PARABO) by Poeppel, T., Eschmann, S., Werner, A., Selkinski, I., Möllers, M.-O., Neußer, T., Benson, A., Kalinovsky, J., Palmedo, H.

Get full text

Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data by Middendorp, M, Selkinski, I, Happel, C, Kranert, W T, Grünwald, F

“…The aim of this study was to retrospectively analyse the value of positron emission tomography (PET) with a radiolabelled somatostatin analogue,…”
Get full text

Risk of malignancy in follicular thyroid neoplasm: predictive value of thyrotropin by Zimny, M, Selkinski, I, Blasius, S, Rink, T, Schroth, H-J, Grünwald, F

“…The cytological diagnosis of follicular neoplasm is a common finding in fine needle aspiration cytology (FNAC) of thyroid nodules and includes benign disease…”
Get more information

Incorporation monitoring of employees of a radioiodine therapy ward. Is incorporation monitoring required for routine? by Happel, C, Kratzel, U, Selkinski, I, Bockisch, B, Etzel, M, Korkusuz, H, Sauter, B, Staudt, J, von Müller, F, Grünwald, F, Kranert, W T

“…Aim of the study was to determine the annual incorporation of staff on a radioiodine therapy ward and the resulting annual effective dose (aed). Following the…”
Get more information

594P Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study by Palmedo, H., Ahmadzadehfar, H., Eschmann, S., Selkinski, I., Straube, F., Niesen, A., Schönberger, J., Barsegian, V., Liepe, K., Mottaghy, F.M., Guan, R., Pinkert, J., Buetikofer, S., Herrmann, K.

Get full text

828PSymptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An interim review of a prospective, non-interventional study (PARABO) by Poeppel, T, Eschmann, S, Werner, A, Selkinski, I, Möllers, M-O, Neußer, T, Benson, A, Kalinovsky, J, Palmedo, H

Get full text

Disease burden and bone health in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO non-interventional study by Poeppel, T.D., Möllers, M., Assa, E., Kalinovsky, J., Benson, A., Selkinski, I.

Get full text

895 - Disease burden and bone health in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO non-interventional study by Poeppel, T.D., Möllers, M., Assa, E., Kalinovsky, J., Benson, A., Selkinski, I.

Get full text